Drug-Induced Liver Injury (DILI) Network Retrospective
ConditionDrug Induced Liver Injury
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age2+
SponsorDuke University
About this trial
The purpose of this study is to establish retrospectively a nationwide registry of patients who have suffered drug-induced liver injury (DILI), and to collect, immortalize, and store serum, DNA, and lymphocytes from these patients. ILIAD will serve as a resource for subsequent mechanistic investigations into the basis of severe idiosyncratic DILI. The primary goal of the ILIAD protocol is to create: (a) a clinical database consisting of individuals who have experienced severe DILI and the relevant clinical data concerning the episode of DILI; and, (b) to create a bank of biological specimens obtained from these individuals. These biological specimens will be DNA, plasma, and immortalized lymphocytes. Immortalized lymphocytes will provide unlimited amounts of genomic DNA for study as well as living immune cells for phenotyping studies.
A secondary goal of the ILIAD protocol is to maintain a registry of cases in the ILIAD database so that they may be recontacted in the future. It is expected that this will facilitate additional studies exploring the mechanisms of DILI.
Eligibility criteria
Qualifiers
The treating gastroenterologist / hepatologist or health care professional must believe that the subject suffered drug-induced liver injury;
The subject must be alive and the date of onset of the qualifying DILI episode must have occurred on or after January 1, 1994;
Evidence of injury that is known or suspected to be related to consumption of a drug or HDS/CAM product
The subject is taking only one of these drugs or HDS agent(s) in the period leading up to the onset of the qualifying DILI episode;
Disqualifiers
are not willing to have medical information and blood samples taken;
are unable to adequately give informed consent to participate in the study including the blood draw for the genetic component;
age < 2 years old at the time of study enrollment (due to blood volume requirements).
Have a competing cause of liver injury such as hepatic ischemia that the investigator felt to be the primary reason for the observed liver injury. Known, pre-existing autoimmune hepatitis; primary biliary cirrhosis, primary sclerosing cholangitis, or other chronic biliary tract disease. Subjects are excluded due to acetaminophen hepatoxicity or liver transplant or allogeneic bone marrow transplant prior to development of drug-CAM induced liver injury.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
400 Participants
are grouped into 2 trial groupsSponsors and collaborators
Duke University
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator
Source ClinicalTrials.gov